FindTrial
Sign In

Expanded Access for AG-221

Expanded Access for AG-221

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03723057
Enrollment
Unknown
Registered
2018-10-29
Start date
Unknown
Completion date
Unknown
Last updated
2019-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

Expanded Access, Compassionate Use

Brief summary

This is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Interventions

DRUGAG-221

Oral AG-221 administered as directed by treating physician.

Sponsors

Celgene
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

\-

Exclusion criteria

\-

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026